Stock Screener App

Gratuito -

Installare

158.75

1.95% -3.16

after-market

Dopo l'orario di chiusura: 159.00 0.25 +0.16%

Astrazeneca Plc (AZN)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Perché AZN Giù? Forum Previsione Frazionamento azionario Storia dei dividendi

Astrazeneca Plc Borsa (AZN) Ultime notizie

Judge Dismisses AstraZeneca’s Bid To Stop Maine Pharmacy Law - Bloomberg Law News

AstraZeneca's drug pipeine is splitting opinion among City analysts - Proactive Investors

ASTRAZENECA : DZ Bank gives a Buy rating - marketscreener.com

ASTRAZENECA : Gets a Buy rating from Berenberg - marketscreener.com

ASTRAZENECA : Gets a Buy rating from Goldman Sachs - marketscreener.com

ASTRAZENECA : UBS remains its Buy rating - marketscreener.com

AstraZeneca reports Phase III results for Ultomiris and Sone-Ve - Clinical Trials Arena

AstraZeneca Stock: What We Thought of Earnings - Morningstar

AstraZeneca Kept at Buy as Berenberg Notes 'Upbeat' Q2 Earnings Call - marketscreener.com

AstraZeneca PLC (AZN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

AZN Q2 FY2026 earnings call - finance.biggo.com

AstraZeneca PLC (AZN) Stock Forecasts - Yahoo Finance

AstraZeneca PLC (AZN) Q2 2026 Earnings Call Highlights: Strong Oncology and Rare Disease Growth ... - Yahoo Finance

AZN Q2 Earnings and Sales Beat, Key Drugs Offset Generic Pressure - TradingView

AstraZeneca’s MONTEROSA Study Tracks Real World Outcomes for STRIDE in Liver Cancer - TipRanks

AstraZeneca: Q2 2026 Results Were All Right, But Farxiga Poses Risks (NYSE:AZN) - Seeking Alpha

AstraZeneca PLC (AZN) Investigation: Bronstein, Gewirtz & Grossma - The National Law Review

AstraZeneca rallies Monday, outperforms market - MarketWatch

AstraZeneca PLC (AZN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

AstraZeneca quarterly net profit rises 2% on strong cancer drug sales - Yahoo Finance UK

Astrazeneca Rises on Profit Beat; Paramount Pauses WBD Deal | Stock Movers - marketscreener.com

AstraZeneca: In line Q2; correction of late is an entry point - marketscreener.com

Dow Jumps Over 400 Points; AstraZeneca Shares Rise After Q2 Earnings - Benzinga

AstraZeneca drug prices evolving in response to Trump policy, executive says - Reuters

AstraZeneca PLC Stock Analysis: Q2 Earnings Beat vs Bearish Trend - The Cryptonomist

Astrazeneca (AZN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance

AstraZeneca says adjusting drug pricing over Trump policies By Investing.com - Investing.com Nigeria

Astrazeneca Q2 Earnings Call Highlights - Yahoo Finance

What's Going on With AstraZeneca Stock Monday?AstraZeneca (NYSE:AZN) - Benzinga

AstraZeneca (NASDAQ: AZN) lifts H1 profit and backs 2026 outlook - Stock Titan

AstraZeneca oncology growth continues despite product setback - Investors' Chronicle

AstraZeneca profit rises on strong cancer drug sales - Yahoo Finance

AstraZeneca Sees 2030 Goal on Track as Cancer Drugs Drive Growth - WSJ

ASTRAZENECA : Jefferies gives a Buy rating - marketscreener.com

Bronstein, Gewirtz & Grossman, LLC Encourages AstraZeneca PLC (AZN) Shareholders to Inquire about Securities Investigation - ACCESS Newswire

Mixed Ultomiris HSCT-TMA results at AstraZeneca (NASDAQ: AZN) spur paediatric filings - Stock Titan

AstraZeneca PLC 2026 Q2ResultsEarnings Call Presentation (NYSE:AZN) 2026-07-27 - Seeking Alpha

AstraZeneca to Acquire Worldwide Rights to Lung Cancer Drug for $600M - Stock Titan

AstraZeneca sales boosted by soaring demand for cancer treatments - Yahoo Finance UK

AstraZeneca (NASDAQ: AZN) Phase III Sone-Ve data show gastric survival gain - Stock Titan

ASTRAZENECA PLC ORD SHS $0.25 (AZN.L) Q2 FY2026 earnings call transcript - Yahoo Finance

AstraZeneca stock edges up on earnings beat despite revenue miss - Investing.com

AstraZeneca Q2 Core Earnings, Revenue Rise; Interim Dividend Raised - marketscreener.com

AstraZeneca PLC Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com

AstraZeneca reiterates guidance after topping Q2 profit expectations; shares up - Investing.com Nigeria

AstraZeneca PLC (AZN) Stock Analysis: Exploring a 26% Potential Upside and Strong Buy Ratings - DirectorsTalk Interviews

Market Open: Vodafone raises guidance, AstraZeneca H1 growth - Yahoo Finance UK

AstraZeneca CFO says AI is not expected to lead to job cuts - marketscreener.com

AstraZeneca sales rise as demand for cancer treatments grow - Yahoo Finance UK

AstraZeneca Logs Higher First-half Profit on Strong Oncology, Rare Disease Drugs Sales; Outlook Maintained - marketscreener.com

AstraZeneca’s Cancer Medicines Spur Profit Growth - Bloomberg

AstraZeneca Q2 Pre-tax Profit Down, But EPS Rise; Backs Positive FY26 View - RTTNews

AstraZeneca Q2 Results: Adjusted EPS rises 141% YoY to $2.63 - scanx.trade

AstraZeneca reports first-half growth, disappointment in Ultomiris trial - Sharecast.com

AstraZeneca quarterly earnings top hopes amid mixed pipeline updates - marketscreener.com

Why is AstraZeneca stock climbing today? By Investing.com - Investing.com Nigeria

AstraZeneca shares climbs as full-year outlook reiterated despite recent trial failureUPDATE - Proactive financial news

AstraZeneca Q2 profit beats estimates as cancer drug sales drive growth (AZN:NYSE) - Seeking Alpha

AstraZeneca Beats Second-Quarter Earnings Forecast - Share Talk

ASTRAZENECA : Receives a Buy rating from JP Morgan - marketscreener.com

AstraZeneca PLC Declares First Interim Dividend for 2026, Payable on September 8, 2026 - marketscreener.com

AstraZeneca PLC Reconfirms Earnings Guidance for the Year 2026 - marketscreener.com

AstraZeneca PLC reports results for the quarter ended June 30Earnings Summary - TradingView

AstraZeneca reports strong first-half growth as pipeline expansion supports long-term outlook - Yahoo Finance UK

AstraZeneca PLC Reports Statistically Significant Improvement in Overall Survival with Sonesitatug Vedotin in CLDN18.2-Positive Advanced Gastric Cancers - marketscreener.com

AstraZeneca's rare disease drug misses main goal in late-stage trial - marketscreener.com

AstraZeneca’s Ultomiris misses primary endpoint in adult HSCT-TMA trial - Investing.com

AstraZeneca Posts Sales Growth on Oncology Strength - marketscreener.com

AstraZeneca’s Sone-Ve shows survival benefit in gastric cancer By Investing.com - Investing.com Nigeria

AstraZeneca’s Ultomiris misses primary endpoint in adult HSCT-TMA trial By Investing.com - Investing.com Canada

AMGN

$414.30

0.70%

NVO

$47.17

1.17%

NVS

$154.61

1.39%

MRK

$130.42

0.38%

GILD

$135.77

2.04%

Apri su Yahoo | Apri su Google | Aperto in Finviz | Apri in MarketWatch | Aperto a EDGAR | Aperto su Reuters